UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No. 001-38148

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Utah		46-2609396
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

(801) 438-1036

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CODX		The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of May 10, 2023, there were 30,263,536 shares of common stock, par value $0.001 per share, outstanding.

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION:

Item 1.	Financial Statements (unaudited):	3

	Consolidated Balance Sheets	3

	Consolidated Statements of Operations	4

	Consolidated Statements of Cash Flows	5

	Consolidated Statements of Stockholders’ Equity	6

	Notes to Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	23

PART II OTHER INFORMATION:

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	24

Item 4.	Mine Safety Disclosures	24

Item 5.	Other Information	24

Item 6.	Exhibits	25

	Signatures	26

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)


	March 31, 2023			December 31, 2022
Assets
Current assets
Cash and cash equivalents	$	6,359,380		$	22,973,803
Marketable investment securities		68,920,535			58,289,066
Accounts receivable, net		2,702,196			3,453,723
Inventory, net		5,294,653			5,310,473
Income taxes receivable		1,695,480			1,870,419
Prepaid expenses and other current assets		913,175			761,187
Note receivable		37,500			75,000
Total current assets		85,922,919			92,733,671
Property and equipment, net		2,510,083			2,539,483
Operating lease right-of-use asset		952,176			372,115
Intangible assets, net		26,661,667			26,768,333
Investment in joint venture		950,001			672,679
Total assets	$	116,996,846		$	123,086,281
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	829,819		$	952,296
Accrued expenses, current		1,492,611			934,447
Operating lease liability, current		277,290			297,209
Contingent consideration liabilities, current		992,229			1,689,471
Deferred revenue		18,120			-
Total current liabilities		3,610,069			3,873,423
Long-term liabilities
Income taxes payable		1,193,080			1,181,284
Deferred tax liability		203,335			2,417,987
Operating lease liability		658,137			50,708
Contingent consideration liabilities		702,455			1,042,885
Total long-term liabilities		2,757,007			4,692,864
Total liabilities		6,367,076			8,566,287
Commitments and contingencies (Note 10)		-			-
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		-			-
Common stock, $0.001 par value; 100,000,000 shares authorized; 34,823,015 shares issued and 30,632,345 shares outstanding as of March 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022		34,823			34,754
Treasury stock, at cost; 4,190,670 and 3,881,658 shares held as of March 31, 2023 and December 31, 2022, respectively		(14,694,062	)		(14,211,866	)
Additional paid-in capital		90,641,608			88,472,935
Accumulated other comprehensive income		471,761			293,140
Accumulated earnings		34,175,640			39,931,031
Total stockholders’ equity		110,629,770			114,519,994
Total liabilities and stockholders’ equity	$	116,996,846		$	123,086,281

See accompanying notes to unaudited consolidated financial statements

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)


	Three Months Ended March 31,
	2023			2022
Revenue	$	601,957		$	22,699,044
Cost of revenue		502,241			3,281,951
Gross profit		99,716			19,417,093
Operating expenses
Sales and marketing		1,706,331			2,652,148
General and administrative		3,013,965			2,922,195
Research and development		5,014,060			3,771,327
Depreciation and amortization		316,010			247,264
Total operating expenses		10,050,366			9,592,934
Income (loss) from operations		(9,950,650	)		9,824,159
Other income
Interest income		202,372			11,393
Realized gain on investments		418,082			-
(Loss) on disposition of assets		-			(93,421	)
Gain on remeasurement of acquisition contingencies		1,037,672			3,379,890
Gain (loss) on equity method investment in joint venture		277,322			(21,339	)
Total other income		1,935,448			3,276,523
Income (loss) before income taxes		(8,015,202	)		13,100,682
Income tax provision (benefit)		(2,259,811	)		1,386,087
Net income (loss)	$	(5,755,391	)	$	11,714,595
Other comprehensive income
Change in net unrealized gains on marketable securities, net of tax	$	178,621		$	-
Total other comprehensive income	$	178,621		$	-
Comprehensive income (loss)	$	(5,576,770	)	$	11,714,595

Earnings per common share:
Basic	$	(0.20	)	$	0.35
Diluted	$	(0.20	)	$	0.34
Weighted average shares outstanding:
Basic		29,483,540			33,935,570
Diluted		29,483,540			34,711,476

See accompanying notes to unaudited consolidated financial statements

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
	2023			2022
Cash flows from operating activities
Net (loss) income	$	(5,755,391	)	$	11,714,595
Adjustments to reconcile net income to cash (used in) provided by operating activities:
Depreciation and amortization		316,010			247,264
Stock-based compensation expense		2,168,742			1,375,097
Change in fair value of acquisition contingencies		(1,037,672	)		(3,379,890	)
Non-cash lease expense		7,449			8,762
(Gain) loss from equity method investment		(277,322	)		21,339
Loss on disposition of assets		-			93,421
Deferred income taxes		(2,214,652	)		(1,359,716	)
Bad debt expense		(114,133	)		47,862
Changes in assets and liabilities:
Accounts receivable		865,660			(871,083	)
Prepaid expenses		60,451			1,042,932
Inventory		15,821			(3,088,944	)
Deferred revenue		18,120			(150,000	)
Income taxes payable		11,796			2,745,803
Accounts payable, accrued expenses and other liabilities		435,686			(641,604	)
Net cash (used in) provided by operating activities		(5,499,435	)		7,805,838
Cash flows from investing activities
Purchases of property and equipment		(179,944	)		(396,600	)
Proceeds from maturities of marketable investment securities		30,539,621			1,255,266
Purchases of marketable securities		(40,992,469	)		-
Net cash (used in) provided by investing activities		(10,632,792	)		858,666
Cash flows from financing activities
Proceeds from exercise of options and warrants		-			150,001
Repurchases of common stock		(482,196	)		-
Net cash (used in) provided by financing activities		(482,196	)		150,001
Net (decrease) increase in cash and cash equivalents		(16,614,423	)		8,814,505
Cash and cash equivalents at beginning of period		22,973,803			88,607,234
Cash and cash equivalents at end of period	$	6,359,380		$	97,421,739
Supplemental disclosure of cash flow information
Interest paid	$	-		$	-
Income taxes paid	$	29,500		$	-
Supplemental disclosure of non-cash investing and financing transactions
Inventory moved to property, plant and equipment	$	-		$	192,056
Right-of-use assets obtained in exchange for new operating lease liabilities	$	657,150		$	681,327

See accompanying notes to unaudited consolidated financial statements

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)


	Convertible Preferred Stock				Common Stock				Treasury			Additional Paid-in		Accumulated Other Comprehensive		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Stock			Capital		Income		Earnings			Equity
Balance as of December 31, 2022		-	$	-		34,754,265	$	34,754	$	(14,211,866	)	$	88,472,935	$	293,140	$	39,931,031		$	114,519,994
Stock-based compensation		-		-		68,750		69		-			2,168,673		-		-			2,168,742
Repurchases of common stock		-		-		-		-		(482,196	)		-		-		-			(482,196	)
Other comprehensive income, net of tax		-		-		-		-		-			-		178,621		-			178,621
Net loss		-		-		-		-		-			-		-		(5,755,391	)		(5,755,391	)
Balance as of March 31, 2023		-	$	-		34,823,015	$	34,823	$	(14,694,062	)	$	90,641,608	$	471,761	$	34,175,640		$	110,629,770

	Convertible Preferred Stock				Common Stock				Treasury		Additional Paid-in		Accumulated Other Comprehensive		Accumulated		Total Stockholders’
	Shares		Amount		Shares		Amount		Stock		Capital		Income		Earnings		Equity
Balance as of December 31, 2021		-	$	-		33,819,862	$	33,820	$	-	$	80,271,999	$	-	$	54,169,279	$	134,475,100
Balance		-	$	-		33,819,862	$	33,820	$	-	$	80,271,999	$	-	$	54,169,279	$	134,475,100
Common stock issued for option exercises		-		-		45,456		45		-		49,956		-		-		50,001
Common stock issued for warrant exercises		-		-		50,000		50		-		99,950		-				100,000
Stock-based compensation		-		-		68,750		69		-		1,375,028		-		-		1,375,097
Net income		-		-		-		-		-		-		-		11,714,595		11,714,595
Net income (loss)		-		-		-		-		-		-		-		11,714,595		11,714,595
Balance as of March 31, 2022		-	$	-		33,984,068	$	33,984	$	-	$	81,796,933	$	-	$	65,883,874	$	147,714,793
Balance		-	$	-		33,984,068	$	33,984	$	-	$	81,796,933	$	-	$	65,883,874	$	147,714,793

See accompanying notes to unaudited consolidated financial statements

CO – DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Overview and Basis of Presentation

Description of Business

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home™ platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee the Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform.

Unaudited Consolidated Financial Statements

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q as they are prescribed for smaller reporting companies. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. These statements should be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed on March 16, 2023.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

Note 2 – Summary of Significant Accounting Policies

Reclassifications

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of March 31, 2023 and December 31, 2022. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

Marketable Investment Securities

The Company’s marketable investment securities are comprised of investments in certificates of deposit and U.S. Treasury bills and notes. The Company designates investments in debt securities as available-for-sale. Available-for-sale debt securities with original maturities of three months or less from the date of purchase are classified within cash and cash equivalents. Available-for-sale debt securities with original maturities longer than three months are available to fund current operations and are classified as marketable investment securities, within current assets on the consolidated balance sheets. The Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. Available-for-sale debt securities are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive income (loss), a component of stockholders’ equity, net of tax. Realized gains and losses on the sale of marketable securities are determined using the average cost method on a first-in, first-out basis and recorded in total other income (expense), net in the condensed consolidated statements of operations and comprehensive income.

The available-for-sale debt securities are subject to a periodic impairment review. For investments in an unrealized loss position, the Company writes down the amortized cost basis of the investment if it is more likely than not that the Company will be required or will intend to sell the investment before recovery of its amortized cost basis. For investments not likely to be sold before recovery of the amortized cost basis, the Company determines whether a credit loss exists by considering information about the collectability of the instrument, current market conditions, and reasonable and supportable forecasts of economic conditions. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate. Allowances for credit losses and write-downs are recognized in total other income (expense), net, and unrealized losses not related to credit losses are recognized in accumulated other comprehensive income (loss). There are no allowances for credit losses recorded for the periods presented.

Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At March 31, 2023, total accounts receivable was $5,686,589 with an allowance for uncollectable accounts of $2,984,393 resulting in a net amount of $2,702,196. At December 31, 2022, total accounts receivable was $6,552,249 with an allowance for uncollectable accounts of $3,098,526 resulting in a net amount of $3,453,723.

Equity-Method Investments

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

Inventory

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At March 31, 2023, the Company had $5,294,653 in inventory, comprised of $1,081,540 of finished goods, and $4,213,113 of raw materials. At December 31, 2022, the Company had $5,310,473 in inventory, of which $1,327,264 was finished goods and $3,983,209 was raw materials. The Company establishes reserves to reduce slow-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

Intangible Assets

Indefinite-lived intangible assets are not amortized, but rather tested for impairment at least annually on December 31, or more often if and when circumstances indicate that the carrying value may not be recoverable. Finite-lived intangible assets are amortized over their useful lives.

Long-lived Assets

Long-lived assets, such as property and equipment, are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

The Company reviews its long-lived assets, including property and equipment, finite-lived intangible assets, and ROU assets, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

Business Combinations

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

Leases

The Company adopted ASC 842, Leases (“ASC 842”) effective January 1, 2022. Under ASC 842, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The Company considers its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses and cost of revenue over the reasonably assured lease term.

The Company has elected to not separate lease and non-lease components for leases of office space and, as a result, accounts for any lease and non-lease components for office space as a single lease component, to the extent they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. The Company’s office leases typically include non-lease components such as common-area maintenance costs. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.

Revenue Recognition

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation.

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

Deferred Revenue

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

Research and Development

Research and development costs are expensed when incurred. For the three months ended March 31, 2023, the Company expensed $5,014,060 of research and development costs, respectively. For the three months ended March 31, 2022, the Company expensed $3,771,327.

Stock-based Compensation

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

Income Taxes

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. The Company has uncertain income tax positions in the consolidated financial statements, and adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

Net Income per Share

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive.

Comprehensive Income

Comprehensive income is comprised of unrealized gains and losses on marketable securities, net of income taxes.

Concentrations Risk and Significant Customers

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the three months ended March 31, 2023. Two customers accounted for approximately 44% of total revenue for the three months ended March 31, 2023. Three customers together accounted for approximately 54% of total revenue for the three months ended March 31, 2022.

Four customers accounted for more than 10% of accounts receivable at March 31, 2023 and one customer accounted for more than 10% of accounts receivable at December 31, 2022. These customers together accounted for approximately 82% and 37% of accounts receivable at March 31, 2023 and December 31, 2022, respectively.

Recently Issued Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

Note 3 - Cash, Cash Equivalents, and Financial Instruments

The following table shows the Company’s cash, cash equivalents, and marketable investment securities by significant investment category:

	March 31, 2023
	Adjusted Cost		Allowance for Credit Losses		Total Unrealized Gains / (Losses)		Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	6,089,090	$	-	$	-	$	6,089,090	$	6,089,090	$	-
Level 1:
Money market funds		270,290		-		-		270,290		270,290		-
Subtotal		270,290		-		-		270,290		270,290		-
Level 2:
U.S. treasury securities		68,294,247		-		626,288		68,920,535		-		68,920,535
Subtotal		68,294,247		-		626,288		68,920,535		-		68,920,535
Total	$	74,653,627	$	-	$	626,288	$	75,279,915	$	6,359,380	$	68,920,535

	December 31, 2022
	Adjusted Cost		Allowance for Credit Losses		Total Unrealized Gains / (Losses)		Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	12,834,444	$	-	$	-	$	12,834,444	$	12,834,444	$	-
Level 1:
Money market funds		146,359		-		-		146,359		146,359		-
Subtotal		146,359		-		-		146,359		146,359		-
Level 2:
U.S. treasury securities		67,892,825		-		389,241		68,282,066		9,993,000		58,289,066
Subtotal		67,892,825		-		389,241		68,282,066		9,993,000		58,289,066
Total	$	80,873,628	$	-	$	389,241	$	81,262,869	$	22,973,803	$	58,289,066

Marketable investment securities held as of March 31, 2023 mature over the next 12 months.

Note 4 – Intangible Assets, Net

Intangible assets, net consisted of the following:

Schedule of Intangible Assets, Net

	March 31, 2023
	Weighted-Average	Gross					Net
	Useful Life (1)	Carrying		Accumulated			Carrying
	(in Years)	Amount		Amortization			Amount
In-process research and development	Indefinite	$	26,101,000	$	-		$	26,101,000
Non-competition agreements	2.7		1,094,000		(533,333	)		560,667
Total intangible assets		$	27,195,000	$	(533,333	)	$	26,661,667

	December 31, 2022
	Weighted-Average	Gross					Net
	Useful Life (1)	Carrying		Accumulated			Carrying
	(in Years)	Amount		Amortization			Amount
In-process research and development	Indefinite	$	26,101,000	$	-		$	26,101,000
Non-competition agreements	2.7		1,094,000		(426,667	)		667,333
Total intangible assets		$	27,195,000	$	(426,667	)	$	26,768,333

(1)

Based on weighted-average useful life established as of the acquisition date.

The expected future annual amortization expense of the Company’s intangible assets held as of March 31, 2023 is as follows:

Schedule of Future Amortization Expense

Year Ending December 31,	Amortization Expense
2023		258,003
2024		302,664
Total	$	560,667

Note 5 – Fair Value Measurements

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, by level within the fair value hierarchy:


	March 31, 2023
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents	$	-	$	298,605	$	-	$	298,605
Marketable securities (U.S. treasury bills and notes)		-		68,920,535		-		68,920,535
Total assets measured at fair value	$	-	$	69,219,140	$	-	$	69,219,140
Liabilities:
Contingent consideration - common stock	$	-	$	-	$	1,467,753	$	1,467,753
Contingent consideration - warrants		-		-		226,931		226,931
Total liabilities measured at fair value	$	-	$	-	$	1,694,684	$	1,694,684


	December 31, 2022
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents	$	-	$	10,179,667	$	-	$	10,179,667
Marketable securities (U.S. treasury bills and notes)		-		58,289,066		-		58,289,066
Total assets measured at fair value	$	-	$	68,468,733	$	-	$	68,468,733
Liabilities:
Contingent consideration - common stock	$	-	$	-	$	2,499,147	$	2,499,147
Contingent consideration - warrants		-		-		233,209		233,209
Total liabilities measured at fair value	$	-	$	-	$	2,732,356	$	2,732,356

The Company’s financial instruments that are measured at fair value on a recurring basis consist of U.S. treasury bills and notes as of March 31, 2023 and December 31, 2022.

In connection with the acquisitions of IdMo and ACI on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculations are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

The changes for Level 3 items measured at fair value on a recurring basis are as follows:


Fair value as of December 31, 2022	$	2,732,356
Change in fair value of contingent consideration issued for business acquisitions		(1,037,672	)
Fair value as of March 31, 2023	$	1,694,684

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of the valuation date. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of the valuation date. Prior to the probability adjustments, the warrants were valued based on the following inputs:

	March 31, 2023			December 31, 2022
Stock price	$	1.48		$	2.52
Strike price	$	9.13		$	9.13
Volatility		117.00	%		75.00	%
Risk-free rate		3.70	%		4.10	%
Expected term		3.8			4.0

Fair Value of Other Financial Instruments

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

Note 6 – Revenue

The following table sets forth revenue by geographic area:

Summary of Revenue by Geographic Area

	Three Months Ended March 31,
	2023			2022
United States	$	393,154		$	14,218,398
Rest of World		208,803			8,480,646
Total	$	601,957		$	22,699,044
Percentage of revenue by area:
United States		65	%		63	%
Rest of World		35	%		37	%

Deferred Revenue

Changes in the Company’s deferred revenue balance for the three months ended March 31, 2023 were as follows:

Schedule of Deferred Revenue

Balance as of December 31, 2022	$	-
Increase due to prepayments from customers		18,120
Balance as of March 31, 2023	$	18,120

Note 7 – Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for three months ended March 31, 2023 and 2022, respectively:

	2023			2022
	Three Months Ended March 31,
	2023			2022
Numerator
Net income, as reported	$	(5,755,391	)	$	11,714,595

Denominator
Weighted average shares, basic		29,483,540			33,935,570
Dilutive effect of stock options, warrants and RSUs		-			775,906
Shares used to compute diluted earnings per share		29,483,540			34,711,476

Basic earnings per share	$	(0.20	)	$	0.35
Diluted earnings per share	$	(0.20	)	$	0.34

For the three months ended March 31, 2022, potentially dilutive securities of 1,271,304 were excluded from the calculation because their effect would have been anti-dilutive. The computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022, respectively, also excludes the approximately 1.4 million shares of common stock and approximately 465,000 warrants to purchase shares of common stock that are contingent upon the achievement of certain milestones.

As a result of incurring a net loss for the three months ended March 31, 2023, no potentially dilutive securities are included in the calculation of diluted earnings per share because such effect would be anti-dilutive. The Company had potentially dilutive securities as of March 31, 2023, consisting of: (i) 2,732,517 restricted stock units and (ii) 120,445 options.

Note 8 – Stock-Based Compensation

Stock Incentive Plans

The Company’s board of directors adopted, and shareholders approved, the Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan (the “Incentive Plan”) providing for the issuance of stock-based incentive awards to employees, officers, consultants, directors and independent contractors. On August 31, 2022, the shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock. The number of awards available for issuance under the Incentive Plan was 5,518,290 at March 31, 2023.

Stock Options

The following table summarizes option activity during the three months ended March 31, 2023:

Schedule of Option Activity

	Number of Options		Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding at December 31, 2022		1,040,572	$	2.19	$	1.37		5.88
Granted		-		-		-
Expired		-		-		-
Forfeited/Cancelled		-		-		-
Exercised		-		-		-
Outstanding at March 31, 2023		1,040,572	$	2.19	$	1.37		5.64

Exercisable at March 31, 2023		1,040,572	$	2.19	$	1.37		5.64

The aggregate intrinsic value of outstanding options at March 31, 2023 was approximately $0.3 million.

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. As of March 31, 2023, there were no unvested options and no unrecognized stock-based compensation expense related to options.

Restricted Stock Units

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the three months ended March 31, 2023:

	Number of RSUs			Weighted Average Grant Date Fair Value
Unvested at December 31, 2022		2,426,725		$	6.95
Granted		692,500			2.82
Vested		(68,750	)		10.23
Forfeited/Cancelled		-			-
Unvested at March 31, 2023		3,050,475		$	5.94

As of March 31, 2023, there was approximately $14.5 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.1 years.

Warrants

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

The following table summarizes warrant activity during the three months ended March 31, 2023:

Schedule of Warrant Activity

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)
Outstanding at December 31, 2022		485,000	$	8.81	$	2.43		4.0
Granted		-		-		-
Expired		-		-		-
Forfeited/Cancelled		-		-		-
Exercised		-		-		-
Outstanding at March 31, 2023		485,000	$	8.81	$	1.09		3.8

There were no warrants exercised during the three months ended March 31, 2023. The intrinsic value of warrants exercised during the three months ended March 31, 2022 was approximately $0.3 million. The aggregate intrinsic value of outstanding warrants at March 31, 2023 was approximately $0.1 million.

The total number of warrants exercisable at March 31, 2023 is 20,000. The ability to exercise the approximately 465,000 warrants issued in connection with acquisitions in prior years is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

Stock-Based Compensation Expense

The Company recognized stock-based compensation expense as follows:


	Three Months Ended March 31,
	2023		2022
Cost of sales	$	12,008	$	12,327
Sales and marketing		529,117		388,017
General and administrative		1,192,214		765,199
Research and development		435,403		209,554
Total stock-based compensation expense	$	2,168,742	$	1,375,097

Note 9 – Income Taxes

For the three months ended March 31, 2023, the Company recognized a benefit from income taxes of $2,259,811, representing an effective tax rate of 28.2%. The Company’s effective tax rate will generally differ from the U.S. Federal statutory rate of 21.0% due to state taxes, permanent items, and discrete items. For the three months ended March 31, 2022, the Company recognized expense from income taxes of $1,386,087.

Note 10 – Commitments and Contingencies

Lease Obligations

The Company leases office space under a non-cancellable operating lease and leases cancellable with one month notice. The Company expenses the cancelable leases in the period incurred in accordance with the practical expedient elected. As such, one lease makes up the entirety of the right-of-use asset and lease liability disclosed. During the three months ended March 31, 2023, this lease was amended to extend the lease term. As a result of this amendment, the Company recognized an additional operating lease liability and corresponding operating right-of-use asset of $657,150.

For the three months ended March 31, 2023, components of lease expense are summarized as follows:

Schedule of Lease Expense

	Three Months Ended March 31, 2023
Operating lease costs	$	87,607
Short-term lease costs		108,678
Total lease costs	$	196,285

Short-term lease costs under month-to-month lease agreements are paid to related parties.

As of March 31, 2023, the maturities of the Company’s lease liabilities are as follows:

	Year Ending December 31,
2023	$	245,226
2024		353,919
2025		368,291
2026		61,680
2027		-
Thereafter		-
Total lease payments		1,029,116
Less: imputed interest		93,689
Present value of operating lease liabilities		935,427
Less: current portion		277,290
Long-term portion	$	658,137

Other information related to operating leases was as follows:

	Three Months Ended March 31, 2023
Cash paid for operating leases included in operating cash flows	$	188,835
Remaining lease term of operating leases		3 years
Discount rate of operating leases		6.7	%

Litigation

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

The Company is a defendant in two class action claims and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to two commercial litigation lawsuits in which plaintiffs are claiming they are owned certain remuneration based on alleged agreements with the Company. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

Note 11 – Share Repurchase Program

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30.0 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular number of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions.

For accounting purposes, common stock repurchased under the stock repurchase program is recorded based upon the transaction date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. These shares are not retired and are considered issued but not outstanding. The following table shows the changes in treasury stock for the periods presented:

Schedule of Treasury Stock

	Three Months Ended
	March 31, 2023
Balance, beginning of period		3,881,658
Repurchases of common stock		309,012
Balance, end of period		4,190,670

Note 12 – Subsequent Events

None.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time, and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Quarterly Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 16, 2023, and the audited financial statements and notes included therein.

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Quarterly Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Quarterly Report to conform our statements to actual results or changed expectations.

You are advised, however, to consult any further disclosures we make on related subjects in our periodic and current reports filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

●	the results of clinical trials and the regulatory approval process;

●	market acceptance of any products that may be approved for commercialization;

●	our ability to protect our intellectual property rights;

●	the impact of any infringement actions or other litigation brought against us;

●	competition from other providers and products;

●	our ability to develop and commercialize new and improved products and services;

●	changes in government regulation;

●	and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

As used in this Quarterly Report, the terms “we”, “us”, “our”, and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

Executive Overview

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying unaudited financial statements and notes thereto included elsewhere in this report. The information contained in this discussion is subject to a number of risks and uncertainties. We urge you to review carefully the section of this report entitled “Cautionary Note Regarding Forward-Looking Statements” for a summary of the risks and uncertainties associated with an investment in our securities.

Business Overview

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We are also developing a unique, groundbreaking portable PCR device and proprietary test cups (the “Co-Dx PCR Home platform”) that have been designed to bring affordable, reliable polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings. This platform is subject to U.S. Food and Drug Administration (“FDA”) review and is not available for sale at the time of this filing. There is no guarantee that our Co-Dx PCR Home platform will receive the necessary regulatory approvals for commercialization, or that, if regulatory approval is received, we will be able to successfully commercialize this platform.

Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification: the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own platform, we believe we will be able to accomplish this faster and more economically than some competitors, allowing for significant margins while still positioning ourselves as a low-cost provider of molecular diagnostics and screening services.

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

Our scientists use the complex mathematics of DNA/RNA PCR test design to engineer and optimize PCR tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Brent Satterfield, our founder, developed the intellectual property we use in our business, consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represent a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended. Verification involves a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

We may either sell or lease the MDx Device to labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary tests to those laboratories and testing facilities.

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and/or in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the Zika virus. In the United States, we obtained Emergency Use Authorization (“EUA”) for our Logix Smart™ COVID-19 detection test from the Food and Drug Administration, or FDA, and we sell that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries.

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describes any type of genetic trait, which creates several significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

RESULTS OF OPERATIONS

The Three Months Ended March 31, 2023 Compared to the Three Months ended March 31, 2022

Revenues

For the three months ended March 31, 2023, we generated revenues of $601,957, compared to revenues of $22,699,044 for the three months ended March 31, 2022. The decrease in revenue of $22,097,087 was primarily due to lower sales of our Logix Smart COVID-19 test developed in response to the COVID-19 pandemic.

Cost of Revenues

We recorded cost of revenues of $502,241 for the three months ended March 31, 2023, compared to $3,281,951 for the three months ended March 31, 2022. The decrease in revenues combined with a larger percentage of fixed product production costs, as well as costs related to expired inventory, resulted in a lower cost of revenues and lower gross margin percentage.

Expenses

We incurred total operating expenses of $10,050,366 for the three months ended March 31, 2023, compared to total operating expenses of $9,592,934 for the three months ended March 31, 2022. The increase in operating expenses was primarily due to increased personnel expenses, including stock-compensation expense, and additional investment in research and development. These increases were partially offset by decreased expenses experienced in conjunction with our decrease in revenues, such as third party sales commissions reflected in sales and marketing and variable compensation.

Our sales and marketing expenses for the three months ended March 31, 2023 were $1,706,331, compared to $2,652,148 for the three months ended March 31, 2022. The decrease was primarily a result of decreased variable compensation, such as bonuses and commissions, and decreased third-party sales commissions, partially offset by increased stock-based compensation expense.

General and administrative expenses increased slightly from $2,922,195 for the three months ended March 31, 2022 to $3,013,965 for the three months ended March 31, 2023. The increase in general and administrative expenses was primarily due to increased insurance expense and professional, legal, and advisory fees, as well as increased stock-based compensation expense, partially offset by decreased variable compensation expense.

Our research and development expenses increased from $3,771,327 for the three months ended March 31, 2022 to $5,014,060 for the three months ended March 31, 2023. The primary increase in expenses was a result of increases in personnel related expenses, increases in materials and supplies expenses related to Co-Dx PCR Home platform development, and increased stock-based compensation expense.

Other Income (expense)

For the three months ended March 31, 2023 we had total other income of $1,935,448, compared to total other income of $3,276,523 for the three months ended March 31, 2022. The primary components of other income include a change in the fair value of contingent consideration liabilities recorded in conjunction with the acquisitions of IdMo and ACI and gains realized from investments in marketable securities.

Net Income (loss)

We realized a net loss for the three months ended March 31, 2023 of $5,755,391, compared with net income for the three months ended March 31, 2022 of $11,714,595. The decrease in net income was primarily the result of a decrease in revenues, combined with an increase of operating expenses, as well as changes in the fair value of acquisition contingencies. Additionally, we recorded an income tax benefit of $2,259,811 for the three months ended March 31, 2023, compared to income tax expense of $1,386,087 for the three months ended March 31, 2022.

Liquidity and Capital Resources

At March 31, 2023, we had cash and cash equivalents of $6,359,380. Additionally, we had $68,920,535 of marketable investment securities that could readily be converted into cash if needed. Additionally, our total current assets of March 31, 2023, were $85,922,919 compared to total current liabilities of $3,610,069.

Net cash used in operating activities during the three months ended March 31, 2023 was $5,499,435, compared to cash provided by operating activities of $7,805,838 for the three months ended March 31, 2022. The decrease in cash from operating activities was primarily due to decreased revenues and the impact of non-cash items.

We used $10,632,792 of cash in investing activities during the three months ended March 31, 2023, primarily from purchases of marketable securities, offset by maturities of marketable investments, compared to cash from investing activities of $858,666 during the three months ended March 31, 2022.

Net cash used in financing activities was $482,196 for the three months ended March 31, 2023, compared to net cash provided by financing activities of $150,001 for the same period in the prior year. This decrease is due to the repurchase of outstanding common shares during the first quarter.

Since commencing sales of our Logix Smart COVID-19 test in March 2020, we have used cash generated from those sales to fund the increase in our inventories and receivables and pay our operating expenses. We have increased our work force primarily in the area of research and development to develop the Co-Dx PCR Home platform and complete development of additional tests to enable us to use our distributor network to sell other products throughout the world and remain profitable in the future. In March 2022 our board of directors authorized the repurchase of up to $30.0 million of the company’s outstanding common stock. We have no obligation to repurchase any shares under the repurchase program and may suspend or discontinue it at any time without prior notice. As of March 31, 2023 we have repurchased 4,190,670 outstanding common shares under the repurchase program for a total of $14.7 million.

Additionally, in March 2023, we filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) with the SEC registering the sale, from time-to-time of up to $150 million of our securities. In connection with the Shelf Registration Statement, we filed an equity distribution agreement prospectus covering the offering, issuance and sale of up to a maximum of $50 million shares of our common stock that may be issued and sold under an equity distribution agreement with Piper Sandler & Co. We are under no obligation to sell any securities under the Shelf Registration Statement or the equity distribution agreement with Piper Sandler & Co.

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities.

If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls were effective.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended March 31, 2023, that have materially affected or, are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

There have been no material developments to the legal proceedings previously disclosed under Part I. Item 3 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

Item 1A. Risk Factors.

Not required under Regulation S-K for “smaller reporting companies.”

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Dividends

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our common stock in the foreseeable future.

Pursuant to Section 16-10a-640 of the Utah Revised Business Corporation Act, no distribution may be made if, after giving it effect:

	(a)	the corporation would not be able to pay its debts as they become due in the usual course of business; or

	(b)	the corporation’s total assets would be less than the sum of its total liabilities plus, unless the articles of incorporation permit otherwise, the amount that would be needed, if the corporation were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.

Share Repurchase Program

Issuer Purchase of Equity Securities
Period	(a) Total number of shares purchased ⁽¹⁾		(b) Average price paid per share ⁽¹⁾		(c ) Total number of shares purchased as part of publicly announced plans or programs ⁽¹⁾		(d) Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs ⁽¹⁾
01/01/23 – 01/31/23		-	$	-		-	$	15,788,134
02/01/23 – 02/28/23		-	$	-		-	$	15,788,134
03/01/23 – 03/31/23		309,012	$	1.56		309,012	$	15,305,938

Total		309,012	$	1.56		309,012	$	15,305,938

(1)

In March 2022 the company announced that its board of directors authorized the repurchase of up to $30.0 million of the company’s outstanding common stock. The extent to which the company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including trading volume, market conditions, legal requirements, business conditions and other factors. The repurchase program may be discontinued at any time, and the program does not obligate the company to acquire any specific number of shares of its common stock.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Index

(a) Exhibits

Exhibit		Number Description

31.1*		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CO-DIAGNOSTICS, INC.

Date: May 11, 2023	By:	/s/ Dwight H. Egan
	Name:	Dwight H. Egan
	Title:	Chief Executive Officer, President and Principal Executive Officer

Date: May 11, 2023	By:	/s/ Brian Brown
	Name:	Brian Brown
	Title:	Chief Financial Officer and Principal Financial and Accounting Officer

SEC Form 10-Q filed by Co-Diagnostics Inc.